IVA

$4.60-$0.08 (-1.71%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$1.1B

236M shares

52-week range

$3.35 – $7.98

27% from low

Exchange

NASDAQ

ADRC

Change$-6.55

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$6M	-30.0%	$-0.67	$-0.79–$-0.55	—	5
2027	$27M	+377.5%	$-0.75	$-0.95–$-0.57	—	4
2028	$248M	+806.4%	$-0.20	$-0.25–$-0.15	—	2
2029	$388M	+56.2%	$-0.02	$-0.02–$-0.02	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 1 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-03-30	$-0.23	$-1.07	-365.2%
2025-09-25	$-0.41	$-1.89	-361.7%
2025-03-26	$-0.44	$-2.19	-398.1%
2024-09-25	$-0.56	$-1.01	-81.1%
2024-03-27	$-0.40	$-1.25	-211.7%
2023-09-28	$-1.27	$-1.43	-13.1%
2023-03-29	$-0.57	$-0.64	-11.9%
2022-09-19	$-0.90

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
IVAInventiva S.A.	$4.60	-1.71%	$239M	—
AVTXAvalo Therapeutics, Inc.	$19.45	-0.51%	$1.0B	—
CRBUCaribou Biosciences, Inc.	$1.61	-5.29%	$160M	—
ENTAEnanta Pharmaceuticals, Inc.	$13.44	-0.44%	$391M	—
EPRXEupraxia Pharmaceuticals Inc.	$6.67	+2.93%

Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

www.inventivapharma.com

Employees: 77
IPO / List date: Jul 10, 2020

Held by traders on TradeandTell

No one on the platform currently holds IVA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in IVA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded IVA yet.

$IVA chatter on StockTwits

Xander@swapo1Bullish3d
$IVA Only a matter of time before this runs off
View on StockTwits ↗
Howard Rosenthal@easymoney_weeee6d
$IVA come down you pos i want more 😆 🤣.
View on StockTwits ↗
full name@nnnuuuBullishAug 6
$IVA people gonna wake up and be surprised when this does +200% on ph3 data
View on StockTwits ↗
laaarsas@laaarsasAug 3
$IVA This might fail
View on StockTwits ↗
Quantumup@QuantumupJul 31
Barclays⬇️ $MDGL to $962 from $964 and reiterated Overweight. $NVO $IVA LLY ALGS VKTX H.C. Wainwright reiterated Madrigal Pharmaceuticals at a Buy rating an a $620 PT. Here's what Barclays and H.C. Wainwright had to say in their notes to investors: https://x.com/Quantumup1/status/2083146910177611788?s=20
View on StockTwits ↗
Pkinla@PkinlaJul 30
$IVA I can’t see this ticker on RH !
View on StockTwits ↗
Wall Street 4 5@Wallst45Jul 29
$IVA why is this down ??
View on StockTwits ↗
Quantumup@QuantumupJul 27
Wells Fargo🏁 $MDGL Overweight-$685—and said in its initiation report that a survey of MD's suggests GLP-1 and competition fears are overdone, supporting durable growth in a multi-drug market—it sees >$7B in peak sales for Rezdiffra. $IVA LLY $NVO ALGS VKTX
View on StockTwits ↗
FONTAINE@POPEYE832Jul 20
@Chucho64 So, I guess it’s time to move to $IVA
View on StockTwits ↗
Quantumup@QuantumupJul 17
Cantor🏁 $IVA and said It Has High Conviction in P3 Success (PoS=90%)—We are initiating coverage of Inventiva ("IVA") with an Overweight (OW) rating. $MDGL NVO $LLY ALGS VKTX SGMT Here's what else Cantor had to say in its initiation report: https://x.com/Quantumup1/status/2078095630807765473?s=20
View on StockTwits ↗
Quantumup@QuantumupJul 17
Citizens⬆️ $MDGL's PT and said -- We reiterate our Market Outperform rating and raise our risk-adjusted, DCF-derived PT on Madrigal Pharmaceuticals to $739 from $737. $IVA $NVO ALGS VKTX Citizens added—MDGL is reporting its 2Q financial results on July 30 at 8 a.m. ET. We lower our 2Q26 Rezdiffra estimate to $354M from $375M to be modestly above consensus of $350M, still representing 14% Q/Q growth. The increase in our PT is primarily a result of slightly lower GTN assumptions (including 37% this year vs. 39% previously). We have not made any changes to our long-term conviction in Rezdiffraās peak sales potential, which we model as >$6B before considering the F4 opportunity.
View on StockTwits ↗
Trainguy1@Trainguy1Jul 9
@boomer165 @howardlindzon If you can wait longer, try $IVA
View on StockTwits ↗
The Legendary Mayor@BioRichBullishJul 8
@Trainguy1 That's a solid list, I like it. $ABVX, $SABS, $EWTX and $IVA all have massive wake up rich potential. I like those conviction plays. Who else do you think I should be following or should be a must hold in my account? Cheers!
View on StockTwits ↗
Djeko@PolipBullishJul 8
$IVA the buyers are bidding.
View on StockTwits ↗
Jon@JonitaBullishJul 7
$IVA 💣💣💣
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.